Molecular classification of metastatic and recurrent endometrial endometrioid carcinoma: prognostic relevance among low‐ and high‐stage tumours
Histopathology · 2024
DOI: 10.1111/his.15232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2024. Verfasst von Austin McHenry und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Carcinoma, Endometrioid, Neoplasm Recurrence, Local, Microsatellite Instability. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: School of Medicine, Stanford University.
Abstract (Originalsprache)
Aims
Molecular classification according to The Cancer Genome Atlas (TCGA) improves endometrial endometrioid carcinoma (EEC) prognostication and has specific treatment implications; however, original data were skewed towards low‐grade and low‐stage tumours. Herein, we molecularly classify EECs metastatic at the time of diagnosis or with subsequently documented recurrent/metastatic disease to examine correlation with clinical outcomes.
Methods
TCGA categories include POLE ‐mutated, microsatellite instability (MSI), p53 abnormal (p53 abnl) and no specific molecular profile (NSMP). POLE targeted sequencing at exons 9, 11, 13 and 14 and immunohistochemistry (IHC) for PMS2, MSH6 and p53 were performed to establish molecular classification.
Results
The distribution in our cohort of 141 EECs was similar to that generally reported in EEC, with nine POLE ‐mutated (6%), 45 MSI (32%), 16 p53 abnl (11%) and 71 NSMP (50%), with similar distributions between low‐ and high‐stage cohorts. We demonstrate that when stratified by molecular subtype, disease‐specific survival from the time of high‐stage (stages III–IV) presentation or time of recurrence in low‐stage (stages I–II) disease among metastatic and/or recurrent EEC is strongly associated with TCGA classification (high‐stage P = 0.02, low‐stage P = 0.017). Discordant molecular classification between primary and metastatic/recurrent tumours occurred in four of 105 (3.8%) patients, two related to PMS2/MSH6 IHC and two related to p53 IHC.
Conclusions
We demonstrate that molecular classification is prognostically relevant not only at the time of diagnosis, but also at the time of recurrence and in the metastatic setting. Rare subclonal alterations occur and suggest a role for confirming TCGA classification in recurrent/metastatic tumours.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
- Stanford University, Stanford, CA, USA.
- Molecular Pathology and Clinical Genomics, Stanford Health Care, Palo Alto, CA, USA.
ORCID-Profile: Austin McHenry, Eric Yang, Brooke E Howitt
Förderung
- School of Medicine, Stanford University
Zitieren
APA
McHenry, A., Devereaux, K., Ryan, E., Chow, S., Allard, G., Ho, C. C., Suarez, C. J., Folkins, A., Yang, E., Longacre, T. A., Charu, V., & Howitt, B. E. (2024). Molecular classification of metastatic and recurrent endometrial endometrioid carcinoma: prognostic relevance among low‐ and high‐stage tumours. Histopathology. https://doi.org/10.1111/his.15232
Vancouver
McHenry A, Devereaux K, Ryan E, Chow S, Allard G, Ho CC, et al. Molecular classification of metastatic and recurrent endometrial endometrioid carcinoma: prognostic relevance among low‐ and high‐stage tumours. Histopathology. 2024. doi:10.1111/his.15232
BibTeX
@article{McHenry2024,
author = {McHenry, Austin and Devereaux, Kelly and Ryan, Emily and Chow, Stephanie and Allard, Grace and Ho, Chandler C and Suarez, Carlos J and Folkins, Ann and Yang, Eric and Longacre, Teri A and Charu, Vivek and Howitt, Brooke E},
title = {Molecular classification of metastatic and recurrent endometrial endometrioid carcinoma: prognostic relevance among low‐ and high‐stage tumours},
journal = {Histopathology},
year = {2024},
doi = {10.1111/his.15232}
}
EUVIMED